BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, August 2, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Dec. 7, 2017

View Archived Issues

S&N finishes up with Rotation Medical buy, prepares for CEO's retirement

Smith & Nephew plc. is ending 2017 by closing its acquisition of Rotation Medical Inc. for $125 million in cash, plus an additional $85 million in potential milestone payments. The London-based company first revealed it would pick up the bioinductive implant-maker back in October in a deal that would be neutral for earnings in 2018 and boost them in 2019. (See BioWorld MedTech, Oct. 24, 2017.) Read More

Cordis and Medinol win FDA nod for Elunir DES

Read More

De novo RTA policy spelled out via pair of checklists

Read More

FDA says direct marking must be routinely revisited

Read More

Lack of certainty adding Brexit-related contingency costs to pharma industry

Read More

Appointments and advancements

Read More

Financings

Read More

Product briefs

Read More

Regulatory front

Read More

Other news to note

Read More

BioWorld Medtech's Orthopedics Extra

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 31, 2026.
  • Illustration of dopamine signaling in the brain

    New schizophrenia targets challenge trial design

    BioWorld
    The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
  • HIV virus

    AIDS 2026: New targets for metabolic dysfunction despite ART

    BioWorld
    Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 28, 2026
  • Jingxin discloses new muscarinic and sigma receptor agonists

    BioWorld Science
    Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing